Login or sign up
For business

Corus Pharma

4.2ยท 12 reviews
Average ratingGreat
4.2/ 5

Based on 12 reviews

542%
433%
325%
20%
10%
Ask AI

Questions about Corus Pharma

Based on 12 reviews, listing data and website checks ยท updated 3 days ago

What is Corus Pharma?

Corus Pharma is a U.S.-based biotech and specialty drug company founded in 2001 that focuses on respiratory and infectious diseases. The company develops and commercializes novel applications and formulations of known therapeutics to treat severe respiratory diseases. Their products include Corus 1020 and 1030, which are designed to treat respiratory infections in cystic fibrosis patients and severe persistent asthma respectively.

What do reviewers praise about Corus Pharma?

Some reviewers on Trustburn praise the company for having a user-friendly website that provides clear and necessary information. They also highlight the helpfulness and responsiveness of the customer service team. Many users express satisfaction with the quality of the products and the commitment to innovation and quality.

How does the company's website perform according to visitors?

The website coruspharma.com is described as easy to navigate and well-designed by multiple reviewers. It provides detailed information about their products and is considered user-friendly by those who have visited it. The site serves as the primary source for learning about their offerings and company details.

What should a first-time customer know about Corus Pharma?

A first-time customer should know that Corus Pharma specializes in developing treatments for severe respiratory diseases like cystic fibrosis and asthma. They focus on creating inhalable forms of antibiotics and anesthetics to address these specific medical needs. Understanding their niche in respiratory therapeutics is key to appreciating their product offerings.

How is Corus Pharma rated on Trustburn?

On Trustburn, Corus Pharma has a rating of 4.2 out of 5 based on 12 reviews.

AI-generated from reviews on this page. Verify anything important with the company directly.

Mary Relling
Reviews 1

๐Ÿ‘ Corus Pharma has been my go-to company for all my pharmaceutical needs. The website is easy to navigate and provides detailed information about their products. The customer service team is always helpful and prompt in assisting me. I have been extremely satisfied with their products and services.

Bill Braunlin
Reviews 1

I recently tried a new pharmaceutical company and was pleasantly surprised by the experience. The website was user-friendly and the information was clear. The support team was knowledgeable and answered all my questions. I would highly recommend them to anyone in need of pharmaceutical products.

Sandra Keiser
Reviews 1

I recently had the opportunity to try Corus Pharma's products and I must say, I'm impressed. The website is user-friendly and provides all the necessary information. The customer service team was polite and helpful. I would definitely recommend their products.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website โ€” a simple way to convert your visitors into customers.

Get the widget for your site →

About Corus Pharma

Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma.

Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.